Minoxidil topique 2 % face à Minoxidil oral 0,25 mg

Data were presented as Mean ± SD, Median * Based on the t-test or Mann-Whitney test. 2% Topical minoxidil Oral minoxidil 0.25 mg p value* solution 0.044±0.003 0.044±0.004 0.805 0.043 (0.035-0.052) 0.043 (0.033-0.056) 0.045±0.003 0.044±0.004 0.956 0.045 (0.035-0.052) 0.046 (0.036-0.056) 0.046±0.004 0.046±0.003 0.889 0.046 (0.036-0.055) 0.048 (0.040-0.050) 0.048±0.003 0.047±0.004 0.778 0.048 (0.042-0.052) 0.048 (0.040-0.052) 102.0±79.2 107.4±21.0 0.259 102.0 (84.0-144.0) 102.0 (60.0-156.0) 106.8±79.2 112.8±126 0.244 102.0 (84.0-144.0) 108.0 (60.0-156.0) 109.8±61.2 115.2±133.2 0.457 108.0 (96.0-132.0) 120.0 (72.0-156.0) 115.8±46.8 113.6±140.4 0.836

Citation complémentaire (methode)

Table 1. Distribution of the hair diameter and density in oral minoxidil 0.25 mg versus topical 2% minoxidil solution for nine months in the treatment of FPHL. Before treatment 3rd month Hair diameter 6th month (mm) 9th month ITT analysis N=51 Before treatment 3rd month Hair density (per cm2) 6th month 9th month

Vahabi-Amlashi S, Layegh P, Kiafar B et al.. A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss.. Dermatol Ther 2021, DOI 10.1111/dth.15131. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Data were presented as Mean ± SD, Median * Based on the t-test or Mann-Whitney test. 2% Topical minoxidil Oral minoxidil 0.25 mg p value* solution 0.044±0.003 0.044±0.004 0.805 0.043 (0.035-0.052) 0.043 (0.033-0.056) 0.045±0.003 0.044±0.004 0.956 0.045 (0.035-0.052) 0.046 (0.036-0.056) 0.046±0.004 0.046±0.003 0.889 0.046 (0.036-0.055) 0.048 (0.040-0.050) 0.048±0.003 0.047±0.004 0.778 0.048 (0.042-0.052) 0.048 (0.040-0.052) 102.0±79.2 107.4±21.0 0.259 102.0 (84.0-144.0) 102.0 (60.0-156.0) 106.8±79.2 112.8±126 0.244 102.0 (84.0-144.0) 108.0 (60.0-156.0) 109.8±61.2 115.2±133.2 0.457 108.0 (96.0-132.0) 120.0 (72.0-156.0) 115.8±46.8 113.6±140.4 0.836

Citation complémentaire (methode)

Table 1. Distribution of the hair diameter and density in oral minoxidil 0.25 mg versus topical 2% minoxidil solution for nine months in the treatment of FPHL. Before treatment 3rd month Hair diameter 6th month (mm) 9th month ITT analysis N=51 Before treatment 3rd month Hair density (per cm2) 6th month 9th month

Vahabi-Amlashi S, Layegh P, Kiafar B et al.. A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss.. Dermatol Ther 2021, DOI 10.1111/dth.15131. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Adverse effects The reported complications were included hirsutism, weight gain, gastrointestinal intolerance, and hypotension, which have not been significantly different in the two treatment groups. (p=0.444). In group 1 (oral minoxidil), two cases (7.7%) of hirsutism, one case (3.8%) of overweight of 4 kg have been observed that were mild and tolerable, and they completed their treatments. Also, two cases (7.7%) with gastrointestinal intolerance and one case of hypotension (3.8%) were excluded from the study. In group 2 (2% topical minoxidil), two cases (8%) of hirsutism have been observed, which was not severe, and no one was excluded due to it (Table 3).

Vahabi-Amlashi S, Layegh P, Kiafar B et al.. A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss.. Dermatol Ther 2021, DOI 10.1111/dth.15131. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Adverse effects The reported complications were included hirsutism, weight gain, gastrointestinal intolerance, and hypotension, which have not been significantly different in the two treatment groups. (p=0.444). In group 1 (oral minoxidil), two cases (7.7%) of hirsutism, one case (3.8%) of overweight of 4 kg have been observed that were mild and tolerable, and they completed their treatments. Also, two cases (7.7%) with gastrointestinal intolerance and one case of hypotension (3.8%) were excluded from the study. In group 2 (2% topical minoxidil), two cases (8%) of hirsutism have been observed, which was not severe, and no one was excluded due to it (Table 3).

Vahabi-Amlashi S, Layegh P, Kiafar B et al.. A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss.. Dermatol Ther 2021, DOI 10.1111/dth.15131. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).